Earnings Reportpositive
Earnings Report
- Company
- EXELIXIS, INC. (EXEL)
Other upcoming events for EXEL
Phase 3 ReadoutPhase 3 Topline: A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants
Phase 3 ReadoutPhase 3 Topline: Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Patent ExpiryPatent/Exclusivity Expiry: COMETRIQ
Patent ExpiryPatent/Exclusivity Expiry: CABOMETYX
Patent ExpiryPatent/Exclusivity Expiry: COTELLIC
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.